Market Price

21.23 

0.34 1.6%

as of May 14 '21

52 Week Range:

20.21 56.59


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Oct '06 Oct '07 Oct '08 Sep '10 Dec '17 Sep '18 Dec '18 Sep '19 Dec '19 Sep '20 Dec '20
Equity (BVPS) 4.42
4.90
growth rate 1.5%
Earnings BIT -91.67
-125.20
-125.71
-114.10
-119.40
-238.85
-219.05
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROA 4.62
6.30
-2.27
4.40
-42.09
-58.27
-80.82
-75.62
growth rate 36.4% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0%
ROE 8.83
11.30
-4.36
15.78
-46.08
-65.58
-98.13
-110.28
growth rate 28.0% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0%
ROIC 5.94
7.37
-2.82
7.95
-46.48
-66.83
-95.53
-85.68
growth rate 24.1% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0%
Cur. Ratio 3.62
2.13
3.88
3.84
12.91
6.36
6.15
11.14
growth rate -41.2% 82.2% -1.0% 236.2% -29.8% -1.7% 34.6%
Quick Ratio 2.80
1.70
3.14
3.29
12.88
6.29
5.85
10.90
growth rate -39.3% 84.7% 4.8% 291.5% -30.1% -3.6% 36.5%
Leverage 1.85
1.75
2.10
3.43
1.09
1.19
1.24
1.53
growth rate -5.4% 20.0% 63.3% -68.2% 4.5% 2.1% 11.1%
Balance Sheet Oct '06 Oct '07 Oct '08 Sep '10 Dec '17 Sep '18 Dec '18 Sep '19 Dec '19 Sep '20 Dec '20
Acct.Receivable 1.53
0.74
1.36
1.70
growth rate -30.4% 35.6% 11.7%
Acct.Payable 7.62
6.75
3.33
5.28
growth rate -5.9% -29.8% 25.9%
Cur.Assets 265.17
142.08
142.08
122.61
122.61
450.45
growth rate -46.4% 0.0% -13.7% 0.0% 91.7%
Total Assets 271.95
150.56
150.56
137.68
137.68
513.69
growth rate -44.6% 0.0% -8.6% 0.0% 93.2%
Cash 262.75
138.81
115.55
439.20
growth rate -27.3% -8.8% 95.0%
Cur.Liabilities 20.55
22.35
22.35
19.94
19.94
40.44
growth rate 8.8% 0.0% -10.8% 0.0% 42.4%
Liabilities 22.78
24.32
24.32
26.53
26.53
178.19
growth rate 6.7% 0.0% 9.1% 0.0% 159.2%
LT Debt 34.78
growth rate
Equity 249.17
126.24
126.24
111.16
111.16
335.51
growth rate -49.3% 0.0% -12.0% 0.0% 73.7%
Common Shares 117.00
132.00
117.00
99.00
59.00
73.25
54.00
73.25
73.00
65.00
growth rate 12.8% -11.4% -15.4% -40.4% 24.2% -26.3% 35.7% -0.3% -5.6%
Cash Flow Statement Oct '06 Oct '07 Oct '08 Sep '10 Dec '17 Sep '18 Dec '18 Sep '19 Dec '19 Sep '20 Dec '20
Capital Expenditures 0.66
0.94
0.94
0.36
0.36
0.80
0.80
growth rate 43.9% 0.0% -62.1% 0.0% 123.7% 0.0%
Cash From OA -74.95
-121.36
-121.36
-121.58
-121.58
-168.73
-168.73
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share 1.09
-1.99
growth rate -100.0%
FCF 53.00
109.00
133.00
107.00
-78.00
-122.31
-124.00
-121.94
-124.00
-169.53
-172.00
growth rate 105.7% 22.0% -19.6% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Oct '06 Oct '07 Oct '08 Sep '10 Dec '17 Sep '18 Dec '18 Sep '19 Dec '19 Sep '20 Dec '20
Sales 1.80
1.14
1.14
2.34
2.34
0.00
growth rate -36.8% 0.0% 105.3% 0.0% -100.0%
Op.Income -91.67
-125.94
-125.71
-119.40
-119.40
-219.26
-219.05
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -89.81
-122.87
-122.87
-115.90
-115.90
-245.96
-245.96
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -89.86
-123.10
-123.10
-116.48
-116.48
-246.29
-246.29
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS 0.56
0.91
-0.36
0.63
-1.53
-2.29
-1.59
-3.77
growth rate 62.5% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0%
Gross Profit -83.73
-116.95
-116.95
-105.20
-141.82
growth rate 0.0% 0.0% 0.0% 0.0%
R&D 118.31
107.54
142.03
growth rate -4.7% 14.9%

Quarterly Statements

Item Name Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Earnings BIT -34.62
-44.42
-44.95
-52.43
-77.79
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Acct.Receivable 1.36
1.70
growth rate 5.7%
Acct.Payable 3.33
6.80
6.15
5.28
growth rate 42.9% -9.6% -14.1%
Cur.Assets 122.61
359.13
506.42
450.45
growth rate 71.2% 41.0% -11.1%
Total Assets 137.68
373.84
521.53
513.69
growth rate 64.8% 39.5% -1.5%
Cash 115.55
348.59
494.42
439.20
growth rate 73.7% 41.8% -11.2%
Cur.Liabilities 19.94
31.37
32.56
40.44
growth rate 25.4% 3.8% 24.2%
Liabilities 26.53
177.54
145.47
178.19
growth rate 158.7% -18.1% 22.5%
LT Debt 32.86
33.79
34.78
growth rate 2.8% 2.9%
Equity 111.16
111.16
196.30
376.06
335.51
growth rate 0.0% 76.6% 91.6% -10.8%
Common Shares 73.25
5.80
6.31
6.31
growth rate -71.9% 9.0% 0.0%
Cash Flow Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Capital Expenditures 0.19
0.11
0.11
0.40
0.17
growth rate -41.8% 0.0% 254.9% -56.6%
Cash From OA -33.66
-36.34
-36.34
-44.35
-51.69
growth rate 0.0% 0.0% 0.0% 0.0%
FCF -33.85
-36.46
-36.46
-44.75
-51.87
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Sales 0.00 0.00 0.00 0.00
growth rate
Op.Income -35.73
-44.42
-44.95
-52.43
-77.79
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -35.17
-84.91
-126.45
-20.33
-55.80
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -35.29
-85.02
-126.56
-20.33
-55.93
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit -30.48
-30.66
-25.95
-32.16
-48.34
growth rate 0.0% 0.0% 0.0% 0.0%
R&D 30.42
25.95
32.16
48.55
growth rate -7.6% 23.9% 51.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is undefined, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE
EPS / Growth 6.4%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 6.4% 28.2% 38.0%
Future PE 0.01 0.01 25.33
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT

Graham Number:

Current EPS is undefined, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.